CD40LG and Respiratory tract infection: The results of this externally controlled study, which used long-term data from Study 2201 and the ESID registry, consistently demonstrated significant reductions in the rate of respiratory tract infections, and serum IgM levels, in participants receiving leniolisib compared with participants receiving current standard of care.